Prevention of stroke and systemic embolization in atrial fibrillation: A Canadian perspective

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 9, 2012, Pages 428-436

  Cairns, John A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atrial fibrillation; Clinical practice guidelines; Oral anticoagulants; Stroke prevention; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; IRBESARTAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTIFICIAL EMBOLISM; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSPEPSIA; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMATURIA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

EID: 84868635144     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1381     Document Type: Review

References (48)

1. Singer DE, Albers GW, Dalen JE, et al.; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation. Chest. 2008; 133: 546S-592S.
2. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchof P, Lip GY, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12: 1360-1420.
3. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: risk of stroke and role of antithrombotic therapy. Circulation. 1991; 84: 469-481.
4. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978; 28: 973-977. (Pubitemid 8401525)
5. Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449-1457.
6. Gage BF, Waterman AD, Shannon, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2670.
7. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110: 2287-2292. (Pubitemid 39407328)
8. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137: 263-272.
9. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342: d124.
10. Lane DA, Lip GY. Female gender is a risk factor for stroke in atrial fibrillation patients. Thromb Haemost. 2009; 101: 802-805.
11. Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011; 9: 39-48.
12. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84: 527-539.
13. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007; 50: 2156-2161. (Pubitemid 350123679)
14. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk. The TRENDS study. Circ Arrhythmia Electrophysiol. 2009; 2: 474-480.
15. Healey JS, Connolly SJ, Gold MR, et al.; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366: 120-129.
16. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke. 1986; 17: 622-626.
17. Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and eminence of stroke: the Framingham Study. Stroke. 1983; 14: 664-667. (Pubitemid 13012334)
18. Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001; 87: 346-349. (Pubitemid 32144882)
19. Skanes AC, Healey JS, Cairns JA, et al.; the CCS Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012; 28: 125-136.
20. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
21. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151: 713-719. (Pubitemid 43290267)
22. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011; 58: 395-401.
23. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk prediction scores in patients with atrial fibrillation undergoing anticoagulation; The AMADEUS (Evaluating the Use of SR34 006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol. 2012; 60: 861-867.
24. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867. (Pubitemid 351650486)
25. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007; 147: 590-592. (Pubitemid 351664513)
26. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
27. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360: 2066-2078.
28. Paikin JS, Eikelboom J, Cairns JA, Hirsh J. New antithrombotic agents - insights from clinical trials. Nat Rev Cardiol. 2010; 7: 498-509.
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
30. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
31. Granger CB, Alexander JH, McMurray JV, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-993.
32. Connolly SJ, Eikelboom J, Joyner C, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.
33. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 20 120 ESC guidelines for the management of atrial fibrillation.*Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Aug 24. [Epub ahead of print].
34. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011; 57. 1330-1337.
35. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012; 60: 738-746.
36. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-2372.
37. Becker RC, Meade TW, Berger PB, et al.; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease:: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 776S-814S. (Pubitemid 351894917)
38. King SB 3rd, Smith SC Jr, Hirshfeld JW, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008; 117: 261-295.
39. Fuster V, Rydén LE, Cannon AS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257-e354. (Pubitemid 44252297)
40. You JJ, Singer DA, Howard PA, et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141; e531S-e575S.
41. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012; 172: 397-402.
42. Hohnloser SH, Oldegren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012; 125: 669-676.
43. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the united states: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011; 4: 26-32.
44. Maringh R, Lane DA, Lip GY. Sever renal impairment and stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2011; 57: 1339-1348.
45. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367: 625-635.
46. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80: 572-586.
47. Cairns JA, Connolly S, McMurtry S, et al.; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011; 27: 74-90.
48. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001; 344: 1411-1420. (Pubitemid 32402097)